Evidence map›Paper›PMID 41244370›Full record

ReviewBMJ oncology2025

Alkylating-induced hypermutation in pancreatic neuroendocrine tumours.

Rodrigo G Taboada, Giovana T Torrezan, Rachel P Riechelmann

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMJ oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rodrigo G TaboadaClinical Oncology, A C Camargo Cancer Center, São Paulo, SP, Brazil.
Giovana T TorrezanFunctional Genomics, A C Camargo Cancer Center, Centro Internacional de Pesquisa, São Paulo, SP, Brazil.
Rachel P RiechelmannACCamargo Cancer Center, Sao Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-0107-9617

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic neuroendocrine tumours (PanNET) represent the most chemosensitive subtype of NET, with alkylating agents being the mainstay treatment for advanced-stage disease. However, disease progression remains inevitable and presents significant clinical challenges. Advances in tumour molecular profiling have facilitated a deeper understanding of the genomic landscape of PanNET, with the aim of guiding therapeutic strategies. Although actionable mutations and elevated tumour mutational burden (TMB) are exceedingly rare in PanNET, they may offer novel therapeutic opportunities. Emerging evidence suggests that treatment with alkylating agents can induce a hypermutator phenotype in a subset of PanNET, characterised by a marked increase in TMB. This genomic evolution may enhance neoantigen load and thereby potentiate responsiveness to immune checkpoint inhibition. This mini review explores hypermutation in PanNET, with a focus on alkylating-induced changes, and considers the potential of immunotherapy in this context.

Indexed as

ChemotherapyImmunotherapyNeuroendocrine tumoursPancreatic cancerTumour biomarkers

Identifiers

PMID41244370
PMCPMC12612724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.